Treatment with anti‐Sclerostin antibody to stimulate mandibular bone formation
Abstract
Anti‐Sclerostin antibody (Scl‐Ab) is a promising new bone anabolic therapy. Although anti‐Scl‐Ab stimulates bone formation and repair in the appendicular and axial skeleton, its efficacy in the craniofacial skeleton is still poorly understood.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 09, 2018
- Source ID
- 10.1002/hed.25128
Entities
People
- Jeffery Markey
- Larry J Suva
- Matthew Tamplen
- P. Daniel Knott
- Tamara Alliston
- Tristan Fowler
Organizations
- National Institutes of Health
- United States Department of Defense
- University of California, San Francisco